ClinicalTrials.gg
CompletedNCT05267769Updated Jul 27, 2022

Clinical Trial on Pharmacokinetics and Tolerability of AP707

A Phase 1 interventional study of AP707 in Pharmacokinetics, Tolerability and Safety, sponsored by CannaXan GmbH. Completed at 1 site in Germany. Open to male participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-27.

Sponsored by CannaXan GmbH · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
30 Years to 60 Years
Sex
Male
01

Study summary

Brief Summary:This study aims to investigate the uptake of AP707, a preparation from cannabis flowers, into the bloodstream after in single administration in healthy volunteers.

Read the detailed description

Pharmacokinetic parameters and tolerability of AP707 is studied over 24 hours after single dose administration in healthy volunteers in a prospective and open-label manner at a single study center.

02

Conditions studied

  • Pharmacokinetics
  • Tolerability
  • Safety

Keywords

  • Cannabis
  • Cannabis based medicine
  • THC
  • Tetrahydrocannabinol
03

In context

Lead sponsor

CannaXan GmbH is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated form
  2. Male at the age of 30 - 60 years at study start
  3. of 18 to 30 kg/m2
  4. Non-smoker, no use of any tobacco products,
  5. Good general health status ( Score = 100; see Annex 1, page 59)
  6. Current without abnormal findings (no significant alterations from normal values, especially with regard to the (QTcF \< 450 ms)
  7. Physical examination, medical history without exclusionary findings
  8. Pulse rate between 50 and 90 bpm
  9. Blood pressure between systolic 90 - 140 mmHg, diastolic 50 - 90 mmHg
  10. Lab values for liver function (, AST, AP, total) within normal ranges
  11. Lab value for renal function (S-Creatinine, according to CKD-EPI) within normal range
  12. Negative test result on I, HIV II, cell surface antigen, antibody
  13. Negative test result of urine screening for Cannabis and substance abuse

Exclusion criteria

Exclusion Criteria:

  1. Medical history of or intolerance to the product or its ingredients or to ingredients of similar chemical structure
  2. Use of Cannabis products within the last 8 weeks
  3. Use of opioids
  4. Former or present dependency (e.g. to alcohol, medicinal products, drugs)
  5. Participation in another clinical trial within the last four weeks prior to study inclusion
  6. Former or present mental illnesses such as severe depression, psychosis, bipolar disorder, mania, obsessive compulsive disorder, and anxiety disorder
  7. Acute severe somatic disease (e.g. gastrointestinal diseases, influenza)
  8. Body temperature ≥ 38°C
  9. Present cardiovascular, respiratory, diabetic, or cancer disease
  10. Hepatitis A, B, C or other liver and renal disease
  11. Other diseases or conditions that do not allow the participant to assess the nature and scope, and possible consequences of participating in this clinical trial
  12. Indications that the participant is unlikely to comply with the study protocol (e.g. lack of cooperation)
  13. Taking any pharmaceutical products (including any medication interacting with metabolism of THC, e.g. St. John's wort)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Verum

    AP707 single dose oromucosal application

    Drug: AP707

Interventions

  • DrugAP707

    Preparation of Cannabis flowers (Cannabis flos)

    Also known as: THC

06

What researchers measure

Primary outcomes

  1. Evaluation of pharmacokinetic parameter of THC (area under the curve)

    Pharmacokinetic outcome of THC measured 0 to 24 hours after application of investigational product

    Time frame: 24 hours

  2. Evaluation of pharmacokinetic parameter of THC (maximum observed drug concentration)

    Pharmacokinetic outcome of THC measured 0 to 24 hours after application of investigational product

    Time frame: 24 hours

  3. Evaluation of pharmacokinetic parameter of THC (time to reach maximum drug concentration)

    Pharmacokinetic outcome of THC measured 0 to 24 hours after application of investigational product

    Time frame: 24 hours

Secondary outcomes

  1. Evaluation of pharmacokinetic parameter of THC (area under the curve from timepoint zero to quantification limits)

    Pharmacokinetic outcome of THC measured 0 to detection limits after application of investigational product

    Time frame: 24 hours

  2. Evaluation of pharmacokinetic parameter of THC (area under the curve from 0 to 24 hours)

    Pharmacokinetic outcome of THC measured 0 to 24 hours after application of investigational product

    Time frame: 24 hours

  3. Evaluation of pharmacokinetic parameter of THC (last drug concentration above quantification limits)

    Pharmacokinetic outcome of THC measured 0 to 24 hours after application of investigational product

    Time frame: 24 hours

  4. Evaluation of pharmacokinetic parameter of THC (time of last drug concentration above quantification limits)

    Pharmacokinetic outcome of THC measured 0 to 24 hours after application of investigational product

    Time frame: 24 hours

  5. Evaluation of pharmacokinetic parameter of THC (half-life associated with the terminal slope)

    Pharmacokinetic outcome of THC measured 0 to 24 hours after application of investigational product

    Time frame: 24 hours

  6. Evaluation of pharmacokinetic parameter of 11-OH-THC (area under the curve)

    Pharmacokinetic outcome of 11-OH-THC measured 0 to 24 hours after application of investigational product

    Time frame: 24 hours

  7. Evaluation of pharmacokinetic parameter of 11-OH-THC (maximum observed drug concentration)

    Pharmacokinetic outcome of 11-OH-THC measured 0 to 24 hours after application of investigational product

    Time frame: 24 hours

  8. Evaluation of pharmacokinetic parameter of 11-OH-THC (time to reach maximum drug concentration)

    Pharmacokinetic outcome of 11-OH-THC measured 0 to 24 hours after application of investigational product

    Time frame: 24 hours

  9. Evaluation of pharmacokinetic parameter of 11-OH-THC (area under the curve from timepoint zero to quantification limits)

    Pharmacokinetic outcome of 11-OH-THC measured 0 to 24 hours after application of investigational product

    Time frame: 24 hours

  10. Evaluation of pharmacokinetic parameter of 11-OH-THC (area under the curve from 0 to 24 hours)

    Pharmacokinetic outcome of 11-OH-THC measured 0 to 24 hours after application of investigational product

    Time frame: 24 hours

  11. Evaluation of pharmacokinetic parameter of 11-OH-THC (last drug concentration above quantification limits)

    Pharmacokinetic outcome of 11-OH-THC measured 0 to 24 hours after application of investigational product

    Time frame: 24 hours

  12. Evaluation of pharmacokinetic parameter of 11-OH-THC (time of last drug concentration above quantification limits)

    Pharmacokinetic outcome of 11-OH-THC measured 0 to 24 hours after application of investigational product

    Time frame: 24 hours

  13. Evaluation of pharmacokinetic parameter of 11-OH-THC (half-life associated with the terminal slope)

    Pharmacokinetic outcome of 11-OH-THC measured 0 to 24 hours after application of investigational product

    Time frame: 24 hours

  14. Adverse events (AE)

    Number and severity of adverse events (AE)

    Time frame: 24 hours

  15. Psychotropic drug effects measured by questionnaire

    Questionnaire comprising 17 questions on intoxication to be answered on numeric rating scale (on a scale from 0 to 10, where 0 means "not at all" (no agreement) and 10 means "extremely" (strongest agreement).

    Time frame: 24 hours

07

Study locations

1 site
  • Phase I Unit of CannaXan GmbH
    Warngau, Bavaria 83627, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Apr 2022, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2022
First posted
Mar 4, 2022
StartActual
Mar 2, 2022
Primary completionActual
Apr 3, 2022
CompletionActual
Apr 3, 2022
Last update
Jul 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05267769
Lead sponsor
CannaXan GmbH
Responsible party
Sponsor
First posted
Mar 4, 2022
Start date
Mar 2, 2022
Primary completion
Apr 3, 2022
Completion
Apr 3, 2022
Last update
Jul 27, 2022

Study contacts

Stefan Lorenzl, Prof. Dr.
principal investigator · Phase I Unit of CannaXan GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion